Direct-acting antiviral (DAA) actions in treatment-naïve patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue , 2011, Pages S52-S58

  Hézode, Christophe ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

DAAs; direct acting antivirals; pegIFN; pegylated interferon; RBV; ribavirin; sustained virological response; SVR

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; TELAPREVIR;

ARTICLE; HEPATITIS C; HUMAN;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS;

MLCS; MLOWN;

EID: 84862740041     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(11)70008-0     Document Type: Article

References (19)

1. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011;55:245–64.
2. Telaprevir EU Summary of Product Characteristics.
3. Boceprevir EU Summary of Product Characteristics.
4. McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., et al. Telaprevir with Peginterferon and ribavirin for chronic HCV genotype I infection. N Engl J Med 360 (2009), 1827–1838.
5. Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009), 1839–1850.
6. Marcellin, P., Forns, X., Goeser, T., Ferenci, P., Nevens, F., Carosi, G., et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 140 (2011), 459–468.
7. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
8. Sherman, K.E., Flamm, S.L., Afdhal, N.H., Nelson, D.R., Sulkowski, M.S., Everson, G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365 (2011), 1014–1024.
9. Kwo, P.Y., Lawitz, E.J., McCone, J., Schiff, E.R., Vierling, J.M., Pound, D., et al. Efficacy of Boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376 (2010), 705–716.
10. Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
11. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009), 399–401.
12. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41 (2009), 1100–1104.
13. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirine therapy for chronic hepatitis C. Nat Genet 41 (2009), 1105–1109.
14. Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138 (2010), 1338–1345.
15. McHutchison, J.G., The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int 31:Suppl 1 (2011), 29–35.
16. Lagging, M., Askarieh, G., Negro, F., Bibert, S., Söderholm, J., Westin, J., et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One, 6, 2011, e17232.
17. Jacobson, I., Catlett, I., Marcellin, P., Bzowej, N.H., Muir, A.J., Adda, N., et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial (Abstract). J Hepatol 54:Suppl 1 (2011), S542–S543.
18. Sulkowski, M., Reddy, K.R., Afdhal, N., Di Bisceglie, A.M., Zeuzem, S., Poordad, F., et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies (Abstract). J Hepatol, 54(Suppl 1), 2011, S195.
19. Sulkowski, M., Poordad, F., Manns, M., Bronowicki, J.P., Reddy, K.R., Harrison, S.A., et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients (Abstract). J Hepatol 54:Suppl 1 (2011), S194–S195.